107 related articles for article (PubMed ID: 27864603)
21. Pulmonary lymphocyte-rich classical Hodgkin lymphoma with early response to ABVD therapy.
Honda A; Nakamura F; Nannya Y; Shintani Y; Fukayama M; Ichikawa M; Kurokawa M
Ann Hematol; 2014 Jun; 93(6):1073-4. PubMed ID: 24173088
[No Abstract] [Full Text] [Related]
22. Low-dose radiation therapy and reduced chemotherapy in childhood Hodgkin's disease: the experience of the French Society of Pediatric Oncology.
Oberlin O; Leverger G; Pacquement H; Raquin MA; Chompret A; Habrand JL; Terrier-Lacombe MJ; Bey P; Bertrand Y; Rubie H
J Clin Oncol; 1992 Oct; 10(10):1602-8. PubMed ID: 1383434
[TBL] [Abstract][Full Text] [Related]
23. Low-dose consolidation radiation therapy for early stage unfavorable Hodgkin lymphoma.
Torok JA; Wu Y; Prosnitz LR; Kim GJ; Beaven AW; Diehl LF; Kelsey CR
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):54-9. PubMed ID: 25863754
[TBL] [Abstract][Full Text] [Related]
24. Decreasing the number of MOPP courses reduces gonadal damage in survivors of childhood Hodgkin disease.
van den Berg H; Furstner F; van den Bos C; Behrendt H
Pediatr Blood Cancer; 2004 Mar; 42(3):210-5. PubMed ID: 14752856
[TBL] [Abstract][Full Text] [Related]
25. [Is the ABVD an optimal regimen for Hodgkins disease?].
Nakamura S
Rinsho Ketsueki; 1998 Feb; 39(2):109-10. PubMed ID: 9545813
[No Abstract] [Full Text] [Related]
26. Long-term follow up of patients with human immunodeficiency virus infection and advanced stage Hodgkin's lymphoma treated with doxorubicin, bleomycin, vinblastine and dacarbazine.
Xicoy B; Miralles P; Morgades M; Rubio R; Valencia ME; Ribera JM
Haematologica; 2013 Aug; 98(8):e85-6. PubMed ID: 23716563
[No Abstract] [Full Text] [Related]
27. Hodgkin lymphoma presenting with multifocal osseous lesions in a child.
Prakash A; Dinand V; Sachdeva A; Yadav SP
Pediatr Hematol Oncol; 2012 Aug; 29(5):424-7. PubMed ID: 22632275
[No Abstract] [Full Text] [Related]
28. Doxorubicin, bleomycin, vinblastine, and dacarbazine alone in treatment of favorable, limited-stage Hodgkin's lymphoma: do we really have robust data?
Basaran G; Agaoglu F; Basaran M
J Clin Oncol; 2010 Sep; 28(27):e485-6; author reply e487. PubMed ID: 20606082
[No Abstract] [Full Text] [Related]
29. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma.
Engert A; Plütschow A; Eich HT; Lohri A; Dörken B; Borchmann P; Berger B; Greil R; Willborn KC; Wilhelm M; Debus J; Eble MJ; Sökler M; Ho A; Rank A; Ganser A; Trümper L; Bokemeyer C; Kirchner H; Schubert J; Král Z; Fuchs M; Müller-Hermelink HK; Müller RP; Diehl V
N Engl J Med; 2010 Aug; 363(7):640-52. PubMed ID: 20818855
[TBL] [Abstract][Full Text] [Related]
30. Interim PET After Two ABVD Cycles in Early-Stage Hodgkin Lymphoma: Outcomes Following the Continuation of Chemotherapy Plus Radiotherapy.
Simontacchi G; Filippi AR; Ciammella P; Buglione M; Saieva C; Magrini SM; Livi L; Iotti C; Botto B; Vaggelli L; Re A; Merli F; Ricardi U
Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):1077-1083. PubMed ID: 26031367
[TBL] [Abstract][Full Text] [Related]
31. Pediatric Hodgkin's disease.
Oliapuram Jose B; Koerner P; Bertolone S; Patel CC; Spanos WJ; Paris KJ; Silverman CL; Yashar CM
J Ky Med Assoc; 2004 Mar; 102(3):104-6. PubMed ID: 15067795
[TBL] [Abstract][Full Text] [Related]
32. A phase II study of dose-dense and dose-intense ABVD (ABVDDD-DI ) without consolidation radiotherapy in patients with advanced Hodgkin lymphoma.
Russo F; Corazzelli G; Frigeri F; Capobianco G; Aloj L; Volzone F; De Chiara A; Bonelli A; Gatani T; Marcacci G; Donnarumma D; Becchimanzi C; de Lutio E; Ionna F; De Filippi R; Lastoria S; Pinto A
Br J Haematol; 2014 Jul; 166(1):118-29. PubMed ID: 24673727
[TBL] [Abstract][Full Text] [Related]
33. G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis.
Evens AM; Cilley J; Ortiz T; Gounder M; Hou N; Rademaker A; Miyata S; Catsaros K; Augustyniak C; Bennett CL; Tallman MS; Variakojis D; Winter JN; Gordon LI
Br J Haematol; 2007 Jun; 137(6):545-52. PubMed ID: 17459049
[TBL] [Abstract][Full Text] [Related]
34. Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5.
Sieber M; Tesch H; Pfistner B; Rueffer U; Lathan B; Brosteanu O; Paulus U; Koch T; Pfreundschuh M; Loeffler M; Engert A; Josting A; Wolf J; Hasenclever D; Franklin J; Duehmke E; Georgii A; Schalk KP; Kirchner H; Doelken G; Munker R; Koch P; Herrmann R; Greil R; Anselmo AP; Diehl V
J Clin Oncol; 2002 Jan; 20(2):476-84. PubMed ID: 11786577
[TBL] [Abstract][Full Text] [Related]
35. [Early results of the treatment of Hodgkin's disease with alternating use in the CVPP and ABVD protocol].
Gabryś K; Kotlarek-Haus S; Sciborski R
Pol Tyg Lek; 1986 Feb; 41(7):195-8. PubMed ID: 2423994
[No Abstract] [Full Text] [Related]
36. Treatment of childhood Hodgkin's disease with ABVD without radiotherapy.
Behrendt H; Brinkhuis M; Van Leeuwen EF
Med Pediatr Oncol; 1996 Apr; 26(4):244-8. PubMed ID: 8600335
[TBL] [Abstract][Full Text] [Related]
37. Comparison of outcomes in studies of advanced Hodgkin's lymphoma.
Johnson PW; Radford JA; Cullen MH; Sydes MR; Stenning SP; Hancock BW
J Clin Oncol; 2006 Jul; 24(20):3309; author reply 3309-10. PubMed ID: 16829655
[No Abstract] [Full Text] [Related]
38. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial.
Eich HT; Diehl V; Görgen H; Pabst T; Markova J; Debus J; Ho A; Dörken B; Rank A; Grosu AL; Wiegel T; Karstens JH; Greil R; Willich N; Schmidberger H; Döhner H; Borchmann P; Müller-Hermelink HK; Müller RP; Engert A
J Clin Oncol; 2010 Sep; 28(27):4199-206. PubMed ID: 20713848
[TBL] [Abstract][Full Text] [Related]
39. Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study.
Hentrich M; Berger M; Wyen C; Siehl J; Rockstroh JK; Müller M; Fätkenheuer G; Seidel E; Nickelsen M; Wolf T; Rieke A; Schürmann D; Schmidmaier R; Planker M; Alt J; Mosthaf F; Engert A; Arasteh K; Hoffmann C
J Clin Oncol; 2012 Nov; 30(33):4117-23. PubMed ID: 23045592
[TBL] [Abstract][Full Text] [Related]
40. Comparison of MOPP/MOPP +/- RT vs. MOPp/ABVD +/- RT in poor prognosis Hodgkin's disease. Long-term results.
Comella P; Abate G; Fiore M; Di Finizio G; Frezza P; Scoppa G; Anania C; Coucourde F; Zarrilli D
J Chemother; 1989 Jul; 1(4 Suppl):1254-6. PubMed ID: 16312855
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
